Revelation Biosciences reports Q3 2023 net loss of $2.6M; cash $14.0M

REVELATION BIOSCIENCES, INC.

2023-Q3 EPS reported $0.41

Net loss $2.6M ($0.42/share) vs loss $1.2M ($1.91/share) in Q3 2022; nine-month net income $2.1M on $8.3M warrant gain.
Cash and equivalents $14.0M at Sep 30, 2023, up from $5.3M at Dec 31, 2022; runway through Sep 2024.
Operating cash burn for nine months 2023 was $5.3M vs $10.3M in 2022, driven by lower clinical study expenses.
Gemini preclinical data showed significant mobilization of neutrophils, monocytes, lymphocytes and upregulation of IL-10, NGAL, IL-6.
Phase 1 clinical study of Gemini expected to begin near end of 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REVELATION BIOSCIENCES, INC. reported three and nine months ended September 30, 2023 results: net income $2.6 million, or $0.42 basic and diluted net loss per share.

Period: three and nine months ended September 30, 2023
Net income: $2.6 million, or $0.42 basic and diluted net loss per share
Result: reported results

Exact text from the filing

Revelation’s net loss for the three months ended September 30, 2023 was $2.6 million, or $0.42 basic and diluted net loss per share, compared to a net loss of $1.2 million, or $1.91 basic and diluted net loss per share for the same period in 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-063019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.